Local manufacturing of 35 APIs (Active Pharmaceutical Ingredients) have started, reducing the dependency on China
Manufacturing of 35 active pharmaceutical ingredients, which have been imported earlier, has started in India under the production linked scheme for the pharmaceuticals sector.
Under the production-linked incentive (PLI) scheme, 32 new plants for the production of APIs have been set up and production has now started. 55 companies, including Sun Pharmaceutical Industries, Aurobindo Pharma, Dr. Reddy’s Laboratories, Lupin, Mylan Laboratories, Cipla and Cadila Healthcare, had qualified for incentives under the scheme.
India has a 90 percent dependence on 35 APIs, which used to be imported earlier. China is the world’s largest producer and exporter of APIs and many of the Indian companies depend on imports of the ingredients to produce formulations. Over 65 percent of India’s API imports come from China.
The products covered under the scheme include formulations, biopharmaceuticals, active pharmaceutical ingredients, key starting material, drug intermediates, and in-vitro diagnostic medical devices, among others.